Q32 Bio Inc. entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. on March 27, 2026, establishing an at-the-market offering program to sell up to $14,200,000 of its common stock. This agreement provides the company with a flexible mechanism to raise capital from time to time at its discretion.
Key takeaways
The company entered into a sales agreement with Cantor Fitzgerald & Co. on March 27, 2026.
The agreement establishes an at-the-market offering program for shares of common stock.
The company may sell shares having an aggregate offering price of up to $14,200,000.
The company will pay Cantor Fitzgerald a cash commission of 3.0% of gross proceeds from sales.
The offering is made pursuant to the company's shelf registration statement on Form S-3 (File No. 333-286491).
The company is not obligated to sell any shares under the agreement and may suspend or terminate the offering.